UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

Cancer cell, 2012-05, Vol.21 (5), p.642-654

2012

Volltextzugriff (PDF)

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors

International journal of cancer, 2013-08, Vol.133 (4), p.788-796

2013

Volltextzugriff (PDF)

Akt inhibitors in clinical development for the treatment of cancer

Expert opinion on investigational drugs, 2010-11, Vol.19 (11), p.1355-1366

2010

Volltextzugriff (PDF)

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

The Lancet (British edition), 2008-08, Vol.372 (9637), p.449-456

2008

Volltextzugriff (PDF)

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis

PloS one, 2012-05, Vol.7 (5), p.e35661-e35661

2012

Volltextzugriff (PDF)

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3584-3590

2009

Volltextzugriff (PDF)

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework

Value in health, 2017-07, Vol.20 (7), p.866-875

2017

Volltextzugriff (PDF)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.354-20, Article 354

2019

Volltextzugriff (PDF)

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational new drugs, 2014-02, Vol.32 (1), p.178-187

2014

Volltextzugriff (PDF)

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1371-1377

2012

Volltextzugriff (PDF)

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

The lancet oncology, 2012-08, Vol.13 (8), p.827-837

2012

Volltextzugriff (PDF)

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

PloS one, 2013-01, Vol.8 (1), p.e54918

2013

Volltextzugriff (PDF)

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2010-01, Vol.28 (3), p.475-480

2010

Volltextzugriff (PDF)

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-01, Vol.24 (1), p.16-24

2006

Volltextzugriff (PDF)

Targeted therapies for non-small cell lung cancer: an evolving landscape

Molecular cancer therapeutics, 2010-07, Vol.9 (7), p.1931-1944

2010

Volltextzugriff (PDF)

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

Cancer, 2009-08, Vol.115 (16), p.3618-3630

2009

Volltextzugriff (PDF)

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

The oncologist (Dayton, Ohio), 2008-10, Vol.13 (10), p.1084-1096

2008

Volltextzugriff (PDF)

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients

NPJ digital medicine, 2018-07, Vol.1 (1), p.27-27, Article 27

2018

Volltextzugriff (PDF)

Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

Journal of clinical oncology, 2007-10, Vol.25 (29), p.4536-4541

2007

Volltextzugriff (PDF)

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Cancer, 2010-03, Vol.116 (5), p.1272-1280

2010

Volltextzugriff (PDF)

Targeted therapies for renal cell carcinoma

Nature reviews. Nephrology, 2017-08, Vol.13 (8), p.496-511

2017

Volltextzugriff (PDF)

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

Urologic Clinics of North America, 2003-11, Vol.30 (4), p.843-852

2003

Volltextzugriff (PDF)

Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2763-2771

2005

Volltextzugriff (PDF)

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

Clinical genitourinary cancer, 2019-06, Vol.17 (3), p.e454-e460

2019

Volltextzugriff (PDF)

Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

Journal of clinical oncology, 2002-12, Vol.20 (23), p.4559-4566

2002

Volltextzugriff (PDF)

1 – 25 von 572

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(526)
Mit Volltextzugriff
(393)

Publikationsform

Artikel
(558)
Buchkapitel
(9)
Reviews
(3)
Berichte
(1)
Texte
(1)

Sprache

Englisch
(570)
Japanisch
(69)
Russisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(329)
Science & Technology
(318)
Life Sciences & Biomedicine
(314)
Oncology
(221)
Biological And Medical Sciences
(183)
Medical Sciences
(178)
Male
(148)
Female
(131)
Kidney Neoplasms - Pathology
(130)
Middle Aged
(123)
Nephrology. Urinary Tract Diseases
(108)
Aged
(107)
Kidneys
(107)
Tumors Of The Urinary System
(107)
Carcinoma, Renal Cell - Pathology
(106)
Carcinoma, Renal Cell - Drug Therapy
(100)
Kidney Neoplasms - Drug Therapy
(98)
Adult
(87)
Tumors
(85)
Carcinoma, Renal Cell - Therapy
(83)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Urology
(87)
Journal Of Clinical Oncology
(73)
Cancer
(50)
Clinical Cancer Research
(37)
Journal Of Immunotherapy
(19)
Cancer Research
(17)
Cancer Treatment And Research
(14)
Kidney Cancer
(14)
Clinical Advances In Hematology & Oncology
(10)
Seminars In Oncology
(10)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors

Akt inhibitors in clinical development for the treatment of cancer

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Targeted therapies for non-small cell lung cancer: an evolving landscape

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients

Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Targeted therapies for renal cell carcinoma

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

Suchergebnisse filtern